Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats

Nutrition Research

Volumn 35, Issue 7, 2015, Pages 576-584

  Pan, Qing Rong ^a   Ren, Yan Long ^b   Liu, Wen Xian ^b   Hu, Yan Jin ^a   Zheng, Jin Su ^a   Xu, Yuan ^a   Wang, Guang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Endoplasmic reticulum stress; Hepatic steatosis; PCR array; Rat; Resveratrol

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; BINDING PROTEIN; BIOLOGICAL MARKER; CHOLESTEROL; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IMMUNOGLOBULIN BINDING PROTEIN; INOSITOL REQUIRING ENZYME 1 ALPHA; INSULIN; INTERLEUKIN 1BETA; LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHOTRANSFERASE; PKR LIKE ER KINASE; RESVERATROL; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; PLANT EXTRACT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; FATTY LIVER; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HISTOPATHOLOGY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER PROTECTION; MALE; NONHUMAN; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION STUDY; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; DYSLIPIDEMIAS; GENE EXPRESSION; GENETICS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYTOTHERAPY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; DIET, HIGH-FAT; DYSLIPIDEMIAS; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYTOTHERAPY; PLANT EXTRACTS; RATS, SPRAGUE-DAWLEY; STILBENES;

EID: 84937517885     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2015.05.006     Document Type: Article

References (51)

1. Williams K.H., Shackel N.A., Gorrell M.D., McLennan S.V., Twigg S.M. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev 2013, 34(1):84-129.
2. Kirimlioglu V., Ara C., Yilmaz M., Ozgor D., Isik B., Sogutlu G., et al. Resveratrol, a red wine constituent polyphenol, protects gastric tissue against the oxidative stress in cholestatic rats. Dig Dis Sci 2006, 51(2):298-302.
3. Penumathsa S.V., Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 2009, 87(4):275-286.
4. Wang B., Sun J., Li X., Zhou Q., Bai J., Shi Y., et al. Resveratrol prevents suppression of regulatory T-cell production, oxidative stress, and inflammation of mice prone or resistant to high-fat diet-induced obesity. Nutr Res 2013, 33(11):971-981.
5. Leifert W.R., Abeywardena M.Y. Cardioprotective actions of grape polyphenols. Nutr Res 2008, 28(11):729-737.
6. Xu Q., Si L.Y. Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action. Nutr Res 2012, 32(9):648-658.
7. Meydani M., Hasan S.T. Dietary polyphenols and obesity. Nutrients 2010, 2(7):737-751.
8. Szkudelski T., Szkudelska K. Anti-diabetic effects of resveratrol. Ann N Y Acad Sci 2011, 1215:34-39.
9. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012, 32(7):537-541.
10. Cho S.J., Jung U.J., Choi M.S. Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice. Br J Nutr 2012, 108(12):2166-2175.
11. Poulsen M.M., Larsen J.O., Hamilton-Dutoit S., Clasen B.F., Jessen N., Paulsen S.K., et al. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res 2012, 32(9):701-708.
12. Gomez-Zorita S., Fernandez-Quintela A., Macarulla M.T., Aguirre L., Hijona E., Bujanda L., et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2012, 107(2):202-210.
13. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., et al. Calorie restriction-like effects of 30days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011, 14(5):612-622.
14. Faghihzadeh F., Adibi P., Rafiei R., Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 2014, 34(10):837-843.
15. Zhang X.Q., Xu C.F., Yu C.H., Chen W.X., Li Y.M. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014, 20(7):1768-1776.
16. Boutant M., Canto C. SIRT1 metabolic actions: Integrating recent advances from mouse models. Mol Metab 2014, 3(1):5-18.
17. Li Y., Xu S., Giles A., Nakamura K., Lee J.W., Hou X., et al. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J 2011, 25(5):1664-1679.
18. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012, 15(5):675-690.
19. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
20. Postic C., Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008, 34(6 Pt 2):643-648.
21. Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):360-369.
22. Goran M.I., Walker R., Allayee H. Genetic-related and carbohydrate-related factors affecting liver fat accumulation. Curr Opin Clin Nutr Metab Care 2012, 15(4):392-396.
23. Tilg H., Moschen A.R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008, 19(10):371-379.
24. Vial G., Dubouchaud H., Leverve X.M. Liver mitochondria and insulin resistance. Acta Biochim Pol 2010, 57(4):389-392.
25. Martinez-Clemente M., Claria J., Titos E. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. Curr Opin Clin Nutr Metab Care 2011, 14(4):347-353.
26. Xin P., Han H., Gao D., Cui W., Yang X., Ying C., et al. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol 2013, 52:12-18.
27. Andersen G., Burkon A., Sulzmaier F.J., Walker J.M., Leckband G., Fuhst R., et al. High dose of dietary resveratrol enhances insulin sensitivity in healthy rats but does not lead to metabolite concentrations effective for SIRT1 expression. Mol Nutr Food Res 2011, 55(8):1197-1206.
28. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127(6):1109-1122.
29. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140(6):900-917.
30. Bailly-Maitre B., Belgardt B.F., Jordan S.D., Coornaert B., von Freyend M.J., Kleinridders A., et al. Hepatic Bax inhibitor-1 inhibits IRE1alpha and protects from obesity-associated insulin resistance and glucose intolerance. J Biol Chem 2010, 285(9):6198-6207.
31. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306(5695):457-461.
32. Lin J.H., Li H., Yasumura D., Cohen H.R., Zhang C., Panning B., et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007, 318(5852):944-949.
33. Oyadomari S., Harding H.P., Zhang Y., Oyadomari M., Ron D. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab 2008, 7(6):520-532.
34. Chypre M., Zaidi N., Smans K. ATP-citrate lyase: a mini-review. Biochem Biophys Res Commun 2012, 422(1):1-4.
35. Wang Q., Jiang L., Wang J., Li S., Yu Y., You J., et al. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology 2009, 49(4):1166-1175.
36. Suchy D., Labuzek K., Machnik G., Kozlowski M., Okopien B. SOCS and diabetes-ups and downs of a turbulent relationship. Cell Biochem Funct 2013, 31(3):181-195.
37. Ueki K., Kondo T., Tseng Y.H., Kahn C.R. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 2004, 101(28):10422-10427.
38. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 2006, 103(9):3444-3449.
39. Qin X., Xie X., Fan Y., Tian J., Guan Y., Wang X., et al. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology 2008, 48(2):432-441.
40. Sprecher D.L., Massien C., Pearce G., Billin A.N., Perlstein I., Willson T.M., et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 2007, 27(2):359-365.
41. Riserus U., Sprecher D., Johnson T., Olson E., Hirschberg S., Liu A., et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57(2):332-339.
42. Asrih M., Jornayvaz F.R. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol 2013, 218(3):R25-R36.
43. Li L., Hai J., Li Z., Zhang Y., Peng H., Li K., et al. Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014, 63:166-173.
44. Bujanda L., Hijona E., Larzabal M., Beraza M., Aldazabal P., Garcia-Urkia N., et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008, 8:40.
45. Heeboll S., Thomsen K.L., Pedersen S.B., Vilstrup H., George J., Gronbaek H. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol 2014, 6(4):188-198.
46. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117):337-342.
47. Alberdi G., Rodriguez V.M., Macarulla M.T., Miranda J., Churruca I., Portillo M.P. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition 2013, 29(3):562-567.
48. Shang J., Chen L.L., Xiao F.X., Sun H., Ding H.C., Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008, 29(6):698-706.
49. Ahn J., Cho I., Kim S., Kwon D., Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 2008, 49(6):1019-1028.
50. Louis X.L., Thandapilly S.J., MohanKumar S.K., Yu L., Taylor C.G., Zahradka P., et al. Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. J Nutr Biochem 2012, 23(9):1163-1169.
51. Crowell J.A., Korytko P.J., Morrissey R.L., Booth T.D., Levine B.S. Resveratrol-associated renal toxicity. Toxicol Sci 2004, 82(2):614-619.